DK0915910T3
(da)
*
|
1996-06-05 |
2006-05-22 |
Roche Diagnostics Gmbh |
Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
|
EP2016950B1
(de)
*
|
1996-08-08 |
2011-01-05 |
Amylin Pharmaceuticals, Inc. |
Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
DK1629849T4
(en)
|
1997-01-07 |
2017-12-04 |
Amylin Pharmaceuticals Llc |
Pharmaceutical compositions comprising exedins and agonists thereof
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
EP1019077B2
(de)
*
|
1997-08-08 |
2010-12-22 |
Amylin Pharmaceuticals, Inc. |
Neue exendinagonist verbindungen
|
EP1938831A1
(de)
*
|
1997-08-08 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
EP1066314B1
(de)
*
|
1997-11-14 |
2007-12-26 |
Amylin Pharmaceuticals, Inc. |
Neuartige exendin agonisten
|
AU2006225176B2
(en)
*
|
1997-11-14 |
2009-01-08 |
Amylin Pharmaceuticals, Llc |
Novel exendin agonist compounds
|
EP1941900A1
(de)
*
|
1997-11-14 |
2008-07-09 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
EP1032587B2
(de)
*
|
1997-11-14 |
2013-03-13 |
Amylin Pharmaceuticals, Inc. |
Neuartige exendin agonisten
|
EP1938830A1
(de)
*
|
1997-11-14 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
AU2003200129B2
(en)
*
|
1997-11-14 |
2006-06-22 |
Amylin Pharmaceuticals, Llc |
Novel Exendin Agonist Compounds
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
ATE366115T1
(de)
*
|
1998-02-13 |
2007-07-15 |
Amylin Pharmaceuticals Inc |
Inotropische und diuretische effekte von exendin und glp-1
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
KR100637433B1
(ko)
|
2004-05-24 |
2006-10-20 |
삼성에스디아이 주식회사 |
발광 표시 장치
|
AU3247799A
(en)
*
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
AU776514B2
(en)
*
|
1998-08-10 |
2004-09-09 |
General Hospital Corporation, The |
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
|
ATE347901T1
(de)
|
1999-01-14 |
2007-01-15 |
Amylin Pharmaceuticals Inc |
Exendine zur glucagon suppression
|
US6902744B1
(en)
|
1999-01-14 |
2005-06-07 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist formulations and methods of administration thereof
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
EP1175443A1
(de)
*
|
1999-04-30 |
2002-01-30 |
Amylin Pharmaceuticals, Inc. |
Modifizierte exendine und exendin agonisten
|
ES2209885T3
(es)
|
1999-05-17 |
2004-07-01 |
Conjuchem, Inc. |
Peptidos insulinotropicos de larga duracion.
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US6506724B1
(en)
*
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
EP1076066A1
(de)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptide zur Senkung des Blutglukosespiegels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1270011A4
(de)
*
|
2000-02-18 |
2003-06-11 |
Sumitomo Pharma |
Wirkstoffe zur verbesserung von gestörter glukosetoleranz
|
US7399304B2
(en)
*
|
2000-03-03 |
2008-07-15 |
C.R. Bard, Inc. |
Endoscopic tissue apposition device with multiple suction ports
|
ES2435094T3
(es)
|
2000-05-19 |
2013-12-18 |
C.R. Bard, Inc. |
Dispositivo y método de captura y sutura de tejido
|
BR0116024A
(pt)
|
2000-12-07 |
2005-12-13 |
Lilly Co Eli |
Proteìna de fusão heteróloga e uso da mesma
|
JP4280070B2
(ja)
|
2001-02-16 |
2009-06-17 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2)
|
US20050148497A1
(en)
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
ATE432289T1
(de)
|
2002-07-04 |
2009-06-15 |
Zealand Pharma As |
Glp-1 und behandlungsmethode für diabetes
|
AU2003268621B2
(en)
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
JP2006506386A
(ja)
*
|
2002-10-22 |
2006-02-23 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
糖尿病の処置
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
CA2545034C
(en)
|
2003-11-20 |
2013-03-05 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
BRPI0507189A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Waratah Pharmaceuticals Inc |
uso combinado de um agonista de glp-1 e compostos de gastrina
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
BRPI0510117A
(pt)
|
2004-04-23 |
2007-09-25 |
Conjuchem Biotechnologies Inc |
método para purificação de conjugados de albumina
|
US8172857B2
(en)
*
|
2004-08-27 |
2012-05-08 |
Davol, Inc. |
Endoscopic tissue apposition device and method of use
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP2127676A3
(de)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Behandlung von Fettleibigkeit und mit Fettleibigkeit zusammenhängenden Erkrankungen und Störungen
|
RU2428431C2
(ru)
|
2004-12-02 |
2011-09-10 |
Домантис Лимитед |
Слитые конструкции лекарственного средства и конъюгаты
|
EP1841448A2
(de)
*
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Pharmazeutische zusammensetzungen und vefahren zur wiederherstellung der betazellmasse und funktion
|
JP4785206B2
(ja)
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン(Exendins)及びその使用
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
NZ561361A
(en)
|
2005-02-11 |
2010-02-26 |
Amylin Pharmaceuticals Inc |
GIP hybrid polypeptides with at least two hormonal activities
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
CN100429227C
(zh)
*
|
2005-06-29 |
2008-10-29 |
常州制药厂有限公司 |
Exendin4多肽片段
|
EP1922336B1
(de)
*
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybridpolypeptide mit auswählbaren eigenschaften
|
EP2347762B1
(de)
|
2005-08-19 |
2019-05-08 |
Amylin Pharmaceuticals, LLC |
Exendin zur diabetesbehandlung und gewichtsreducierung
|
JP5222727B2
(ja)
*
|
2005-09-06 |
2013-06-26 |
オーラメッド・ファーマスーティカルズ・インコーポレイテッド |
タンパク質を経口投与するための方法及び組成物
|
US20090181887A1
(en)
*
|
2005-09-08 |
2009-07-16 |
Gastrotech Pharma A/S |
Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
|
ES2397289T3
(es)
*
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
US20070269863A1
(en)
*
|
2005-12-22 |
2007-11-22 |
Bridon Dominique P |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
EP1854455B1
(de)
*
|
2006-05-10 |
2009-10-07 |
Biocompatibles UK Limited |
GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
ES2398126T3
(es)
|
2006-08-09 |
2013-03-13 |
Intarcia Therapeutics, Inc |
Sistemas de liberación osmótica y unidades de pistón
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
CL2007002634A1
(es)
*
|
2006-09-13 |
2008-05-16 |
Smithkline Beecham Corp |
Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
EP1972349A1
(de)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
|
WO2008116294A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Matregen Corp. |
Exendin analogs
|
EP1975176A1
(de)
*
|
2007-03-27 |
2008-10-01 |
Biocompatibles UK Limited |
Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
WO2008134425A1
(en)
*
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
WO2009043478A2
(en)
*
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
CN102026666B
(zh)
*
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发(河北)有限公司 |
促胰岛素肽缀合物制剂
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
EP2279244B1
(de)
|
2008-03-26 |
2020-07-01 |
Oramed Ltd. |
Verfahren und zusammensetzungen zur oralen verabreichung von proteinen
|
BRPI0909397A2
(pt)
|
2008-03-31 |
2015-12-15 |
Glaxo Group Ltd |
composição, uso de uma composição, formulação, dispositivo de liberação, ácido nucléico, vetor, célula hospedeira, e, métodos para produzir um polipeptídeo de fusão
|
BRPI0908292B1
(pt)
|
2008-05-05 |
2022-09-20 |
Oramed Ltd |
Métodos e composições para administração oral de exenatida
|
ES2552646T3
(es)
|
2008-05-21 |
2015-12-01 |
Amylin Pharmaceuticals, Inc. |
Exendinas para disminuir el colesterol y los triglicéridos
|
CA2731236A1
(en)
*
|
2008-07-21 |
2010-01-28 |
Transpharma Medical Ltd. |
Transdermal system for extended delivery of incretins and incretin mimetic peptides
|
EP3741359A1
(de)
*
|
2008-08-18 |
2020-11-25 |
Entera Bio Ltd. |
Verfahren und zusammensetzungen zur oralen verabreichung von proteinen
|
MX352189B
(es)
|
2008-09-04 |
2017-11-10 |
Amylin Pharmaceuticals Llc |
Formulaciones de liberación sostenida usando portadores no acuosos.
|
EP2163243A1
(de)
*
|
2008-09-12 |
2010-03-17 |
Biocompatibles UK Limited |
Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
|
RS56632B1
(sr)
|
2008-10-17 |
2018-03-30 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
PL2373681T3
(pl)
|
2008-12-10 |
2017-07-31 |
Glaxosmithkline Llc |
Kompozycje farmaceutyczne albiglutydu
|
CN104127880A
(zh)
|
2009-03-27 |
2014-11-05 |
葛兰素集团有限公司 |
药用融合体和缀合物
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
KR101321461B1
(ko)
*
|
2009-08-10 |
2013-10-29 |
아크레이 가부시키가이샤 |
췌도 이미징용 분자 프로브 및 그 전구체, 및 그들의 사용
|
NZ747990A
(en)
|
2009-09-28 |
2020-06-26 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
AU2010303112A1
(en)
|
2009-09-30 |
2012-04-26 |
Glaxo Group Limited |
Drug fusions and conjugates with extended half life
|
EP2496249B1
(de)
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Glp-1-rezeptor-agonisten zur verwendung in der behandlung von obstruktiver schlafapnoe
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
ES2855146T3
(es)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
CN102770152B
(zh)
|
2009-11-25 |
2016-07-06 |
阿瑞斯根股份有限公司 |
肽类的粘膜递送
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
JP5969461B2
(ja)
|
2010-04-27 |
2016-08-17 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
|
EP2566502A4
(de)
|
2010-05-04 |
2013-10-09 |
Glaxosmithkline Llc |
Verfahren zur behandlung oder prävention von herz-kreislauf-erkrankungen und für herz-kreislauf-schutz
|
HUE031181T2
(en)
|
2010-08-30 |
2017-06-28 |
Sanofi Aventis Deutschland |
Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
|
CA2812951A1
(en)
|
2010-09-28 |
2012-04-19 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action
|
JP2014504588A
(ja)
|
2010-12-22 |
2014-02-24 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
膵島細胞移植のためのglp−1受容体アゴニスト
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
HUE028568T2
(en)
|
2011-10-04 |
2016-12-28 |
Sanofi Aventis Deutschland |
For use in the treatment of constriction and / or obstruction of the lysine senate and pancreatic duct system
|
EP2763691A1
(de)
|
2011-10-04 |
2014-08-13 |
Sanofi-Aventis Deutschland GmbH |
Glp-1-agonist zur verwendung bei der behandlung von stenose und/oder verstopfungen im pankreasgangsystem
|
CA2853884A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
CN104159598A
(zh)
|
2012-01-03 |
2014-11-19 |
奥拉姆德有限公司 |
治疗糖尿病的方法和组合物
|
EP4082530B1
(de)
|
2012-02-01 |
2024-04-10 |
Oramed Ltd. |
Proteaseinhibitorhaltige zusammensetzungen, zusammensetzungen damit und verfahren zur herstellung und verwendung davon
|
AU2013261214A1
(en)
|
2012-05-16 |
2014-11-20 |
Glaxo Group Limited |
Polypeptide loaded POCA nanoparticles for oral administration
|
CN104302772B
(zh)
|
2012-05-18 |
2017-11-10 |
爱德迪安(北京)生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
WO2013186240A2
(en)
|
2012-06-14 |
2013-12-19 |
Sanofi |
Exendin-4 peptide analogues
|
WO2014016300A1
(en)
|
2012-07-23 |
2014-01-30 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
CN104902919B
(zh)
|
2012-12-21 |
2018-11-20 |
赛诺菲 |
Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
|
EP2941267B1
(de)
|
2013-01-03 |
2022-11-16 |
Oramed Ltd. |
Zusammensetzungen zur verwendung in der behandlung von nafld
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
WO2014178018A1
(en)
|
2013-05-02 |
2014-11-06 |
Glaxosmithkline Intellectual Property Development Limited |
Therapeutic peptides
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
BR112016008115B1
(pt)
|
2013-10-17 |
2024-03-12 |
Boehringer Ingelheim International Gmbh |
Análogos de glucagon acilados
|
BR112016009995B1
(pt)
|
2013-11-06 |
2023-04-18 |
Zealand Pharma A/S |
Compostos agonistas triplos glucagon-glp-1-gip
|
WO2015067715A2
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
WO2015081891A1
(en)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
EP3080150B1
(de)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/gip受體促效劑
|
EP3080152A1
(de)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Nicht-acylierte exendin-4-peptidanaloga
|
US9839692B2
(en)
|
2014-01-09 |
2017-12-12 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
BR112016013832A2
(pt)
|
2014-01-09 |
2017-08-08 |
Sanofi Sa |
Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
|
EP3091964A1
(de)
|
2014-01-09 |
2016-11-16 |
Sanofi |
Stabilisierte pharmazeutische formulierungen von insulin aspart
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
RU2573933C1
(ru)
|
2014-08-21 |
2016-01-27 |
Дафот Энтерпрайсис Лимитед |
Пептид для лечения сахарного диабета 2-го типа и его осложнений
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
JP6898231B6
(ja)
|
2014-10-29 |
2021-07-28 |
ジーランド ファーマ アクティーゼルスカブ |
Gipアゴニスト化合物及び方法
|
JP6970615B2
(ja)
|
2014-12-12 |
2021-11-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリングラルギン/リキシセナチド固定比処方
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
ES2763329T3
(es)
|
2015-04-16 |
2020-05-28 |
Zealand Pharma As |
Análogo de glucagón acilado
|
HRP20211768T1
(hr)
|
2015-05-22 |
2022-02-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Liječenje postbarijatrijske hipoglikemije s antagonistima glp-1
|
NZ738102A
(en)
|
2015-06-03 |
2024-02-23 |
Intarcia Therapeutics Inc |
Implant placement and removal systems
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
|
ES2958531T3
(es)
|
2015-10-14 |
2024-02-09 |
X Therma Inc |
Composiciones y métodos para reducir la formación de cristales de hielo
|
KR20180108602A
(ko)
|
2015-12-23 |
2018-10-04 |
암젠 인크 |
위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
|
WO2017152014A1
(en)
|
2016-03-04 |
2017-09-08 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
|
WO2017178829A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Imperial Innovations Limited |
Peptide analogues
|
TWI814219B
(zh)
|
2016-05-16 |
2023-09-01 |
美商因塔希亞治療公司 |
升糖素受體選擇性多肽和彼之使用方法
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
WO2018057977A1
(en)
|
2016-09-23 |
2018-03-29 |
Delpor, Inc. |
Stable compositions for incretin mimetic compounds
|
BR112019010236A2
(pt)
|
2016-11-21 |
2019-08-20 |
Eiger Biopharmaceuticals Inc |
formulações tamponadas de exendina (9-39)
|
US11285180B2
(en)
|
2016-12-06 |
2022-03-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
US10835580B2
(en)
|
2017-01-03 |
2020-11-17 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
MX2019013919A
(es)
|
2017-06-20 |
2020-01-21 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
|
TWI762706B
(zh)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
KR20200142032A
(ko)
|
2018-04-10 |
2020-12-21 |
사노피-아벤티스 도이칠란트 게엠베하 |
캡핑을 사용한 릭시세나티드 합성
|
US11560402B2
(en)
|
2018-04-10 |
2023-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Method for cleavage of solid phase-bound peptides from the solid phase
|
USD933219S1
(en)
|
2018-07-13 |
2021-10-12 |
Intarcia Therapeutics, Inc. |
Implant removal tool and assembly
|
CA3131912A1
(en)
|
2019-03-08 |
2020-09-17 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
TW202140063A
(zh)
|
2020-02-18 |
2021-11-01 |
丹麥商諾佛 儂迪克股份有限公司 |
醫藥配方
|